Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1IMpassion-130 (PDL1>1%), 20182KEYNOTE-355 (CPS>1), 2020 KEYNOTE-355 (CPS>10), 20201IMpassion-131 (PD-L1 > 1%), 2020atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel 0.64 [0.40; 1.03]0.64 [0.40;1.03]atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel 0.64 [0.40; 1.03]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.87 [0.63; 1.19]0.87 [0.63;1.19]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.87 [0.63; 1.19]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) atezolizumab plus nab-paclitaxel better 0.71 [0.54; 0.94]0.71 [0.54;0.94]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) atezolizumab plus nab-paclitaxel better 0.71 [0.54; 0.94]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel 1.56 [0.97; 2.51]1.56 [0.97;2.51]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel 1.56 [0.97; 2.51]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC 1.36 [0.90; 2.05]1.36 [0.90;2.05]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC 1.36 [0.90; 2.05]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.11 [0.76; 1.63]1.11 [0.76;1.63]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.11 [0.76; 1.63]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.15 [0.84; 1.58]1.15 [0.84;1.58]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.15 [0.84; 1.58]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel 0.74 [0.49; 1.11]0.74 [0.49;1.11]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel 0.74 [0.49; 1.11]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.82 [0.70; 0.95]0.82 [0.70;0.95]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.82 [0.70; 0.95]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.41 [1.07; 1.86]1.41 [1.07;1.86]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.41 [1.07; 1.86]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.90 [0.61; 1.32]0.90 [0.61;1.32]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.90 [0.61; 1.32]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.22 [1.05; 1.43]1.22 [1.05;1.43]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.22 [1.05; 1.43]Standard of Care (SoC)placebo plus SoCatezolizumab plus nab-paclitaxelpembrolizumab plus SoCatezolizumab plus paclitaxeldirect evidencenetwork meta-analysis
T vs. C Standard of Care (SoC)placebo plus SoCatezolizumab plus nab-paclitaxelpembrolizumab plus SoCatezolizumab plus paclitaxel
Standard of Care (SoC)---NA1.41
1.07; 1.86		1.22
1.05; 1.43		0.90
0.61; 1.32
placebo plus SoCNA---NANANA
atezolizumab plus nab-paclitaxel0.71
0.54; 0.94		NA---0.87
0.63; 1.19		0.64
0.40; 1.03
pembrolizumab plus SoC0.82
0.70; 0.95		NA1.15
0.84; 1.58		---0.74
0.49; 1.11
atezolizumab plus paclitaxel1.11
0.76; 1.63		NA1.56
0.97; 2.51		1.36
0.90; 2.05		---

pathologies: 143 - treatments: 1283 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons